September 2025 in “International Journal of Women’s Dermatology” Oral spironolactone effectively promotes hair growth in premenopausal women but may cause irregular menstruation.
44 citations
,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
18 citations
,
March 2010 in “Gynecologic and obstetric investigation” The oral contraceptive alone is the preferred treatment for hirsutism, as adding the GnRH analog showed no significant benefit.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
3 citations
,
November 2018 in “The Journal of Clinical Psychiatry” Odds Ratios can be misleading; it's better to also present risk and Relative Risks for clarity.
1 citations
,
January 2022 in “European Journal of Pharmacology” Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.
51 citations
,
April 1999 in “The Journal of Steroid Biochemistry and Molecular Biology” Testosterone replacement may improve sexual desire and bone health in women with low androgen levels, but more research is needed on its long-term safety.
April 2026 in “Journal of the American Academy of Dermatology” Oral 5-alpha-reductase inhibitors for hair loss don't increase heart risk.
60 citations
,
June 1997 in “Drugs & Aging” Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.
5 citations
,
January 1991 in “Drugs of The Future”
26 citations
,
October 2011 in “International Journal of Biological Macromolecules” Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
9 citations
,
April 2018 in “JAMA Dermatology” Topical minoxidil improves hair loss in 80% of women with breast cancer undergoing endocrine therapy.
11 citations
,
November 2009 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Bolandiol, a synthetic steroid, builds muscle and bone without greatly affecting sex glands, and works differently from other hormones.
1 citations
,
September 2016 in “Actas Dermo-Sifiliográficas” 5-alpha reductase inhibitors may cause sexual side effects, breast complications, and other health risks in men with hair loss.
March 2026 in “International Journal of Pharmacology” Flaxseed lignans may reduce breast cancer risk in women.
June 1995 in “International Journal of Gynecology & Obstetrics” Higher doses of oestradiol implants improve bone density in postmenopausal women.
January 2025 in “Reactions Weekly” November 2024 in “Reactions Weekly” May 2023 in “Reactions Weekly”
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
1 citations
,
July 2025 in “Functional Foods in Health and Disease” CL22209, an Asparagus racemosus extract, safely reduces perimenopausal symptoms and balances hormones.
1 citations
,
August 2024 in “Indian Dermatology Online Journal” Bicalutamide may effectively treat female pattern hair loss with minimal side effects.
203 citations
,
December 1947 in “Annals of Internal Medicine” September 2024 in “Chemico-Biological Interactions” Finasteride improves heart function in obese and aging male rats by reducing oxidative stress and p53 protein levels.
16 citations
,
May 2020 in “Frontiers in pharmacology” Minoxidil can stop the growth of ovarian cancer cells without harming the heart.
33 citations
,
January 2016 in “Skin appendage disorders” The document concludes that sexual and psychiatric side effects from 5-alpha-reductase inhibitors are reported, but more high-quality research is needed to understand how often they occur.
February 2013 in “Journal of The American Academy of Dermatology” Using hair loss drugs finasteride and dutasteride may cause sexual side effects.
11 citations
,
September 2012 in “Journal of obstetrics and gynaecology Canada” Testosterone therapy seems safe for short-term use in postmenopausal women with low sexual desire, but more research on long-term effects is needed.
4 citations
,
April 2009 in “Journal of Pain” Finasteride boosts morphine's pain relief and prevents tolerance and withdrawal in rats.